News & Information

Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma® Life Science, extended CompoZr® Zinc Finger Nuclease (ZFN) technology to achieve the first tissue-specific conditional knockout of an endogenous gene in rats. For two decades this approach for generating sophisticated disease models could be performed only in mice. Rats, however, are preferred by drug discovery and basic researchers because the animal’s physiology, neurobiology and other features are more predictive of human conditions. Rats engineered to contain tissue-specific conditional gene knockouts are available exclusively through the SAGEspeed™ Custom Model Development Service. Details are available at www.sageresearchmodels.com/conditional-KO.

Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), is launching the CHOZN® Platform system, a CHO (Chinese Hamster Ovary) cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs. The new platform consists of the cGMP-produced and tested CHOZN® ZFN Modified GS-/- CHO cell line, an optimized set of cGMP-produced, chemically defined media and specially designed feeds to maximize production of r-proteins.

Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it has acquired all outstanding shares of Cleveland, Ohio-based, Research Organics, Inc., to expand the Company's buffer production capacity and to increase its portfolio of PharmaGrade raw materials for the biopharmaceutical and diagnostic markets. Research Organics is a leading supplier of high purity biochemicals for use in molecular biology, diagnostics, cell culture, pharmaceuticals, biopharmaceuticals, life sciences and biotechnology and will transition into SAFC, the custom manufacturing and services business unit of Sigma-Aldrich.